Skip to main content
Tevogen Bio Holdings Inc. logo

Tevogen Bio Holdings Inc. — Investor Relations & Filings

Ticker · TVGN ISIN · US88165K1016 US Professional, scientific and technical activities
Open in API
Filings indexed 269 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country US United States of America
Listing US TVGN

About Tevogen Bio Holdings Inc.

https://tevogen.com/

Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company developing off-the-shelf, precision T cell therapies. The company utilizes its proprietary ExacTcell™ technology platform to harness the therapeutic potential of CD8+ cytotoxic T lymphocytes (CTLs), a key component of the natural immune system. This platform is designed to create treatments that specifically target antigens present only on diseased cells, thereby preserving healthy tissue and enhancing safety through the use of naturally occurring T cell receptors. The company's development pipeline addresses significant unmet medical needs across multiple therapeutic areas, including oncology, virology, and neurology, with a stated goal of providing affordable and accessible personalized therapies to large patient populations.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q1 2026
2026-05-15 English
8-K - Tevogen Bio Holdings Inc. (0001860871) (Filer)
Delisting Announcement Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 16, 2026, by Tevogen Bio Holdings Inc. The key content is a notice regarding the company's failure to meet Nasdaq's minimum market value listing requirements, specifically the $50 million minimum market value for listed securities and the $15 million minimum market value of publicly held shares. The document details the notification from Nasdaq, the compliance deadlines, and the company's intentions regarding regaining compliance or transferring to another market. This is a regulatory announcement about the company's listing status and compliance with exchange rules, specifically a notice of delisting or failure to satisfy continued listing standards. The document is not a full financial report, earnings release, or management discussion, but a formal notice of delisting risk. Therefore, the appropriate classification is Delisting Announcement (DLST). The document length and content support this classification with high confidence.
2026-04-22 English
10-K - Tevogen Bio Holdings Inc. (0001860871) (Filer)
Annual Report FY 2025
2026-03-31 English
4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)
Director's Dealing
2026-03-17 English
8-K - TEVOGEN BIO HOLDINGS INC. (0001860871) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content specifically details a reverse stock split, including the amendment to the Certificate of Incorporation, effects on shares, CUSIP number changes, and related procedural information. It also references a press release and includes exhibits related to the amendment and the press release. This filing is not a full financial report, earnings release, or management discussion, but rather a regulatory announcement about a capital structure change (reverse stock split). According to the filing definitions, updates on capital structure changes such as reverse stock splits fall under Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about the capital change, not just a brief announcement or a certification. Therefore, the appropriate classification is CAP with high confidence.
2026-03-04 English
8-K - TEVOGEN BIO HOLDINGS INC. (0001860871) (Filer)
Regulatory Filings Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 19, 2026. It reports on a special meeting of stockholders where proposals were voted on, including an amendment to the 2024 Omnibus Incentive Plan and a reverse stock split. The document includes voting results and references to exhibits but does not contain financial statements or detailed financial analysis. It is a regulatory announcement of corporate governance and shareholder voting outcomes rather than a full report or financial disclosure. Therefore, it fits best under Regulatory Filings (RNS).
2026-02-25 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.